Hello Part-time Trader…👋

Premium Stock Alerts is here with your pre-market cheat sheet. In today's issue, we delve into:

• Fed's Latest Announcements: Understand the Federal Reserve's recent decisions and economic outlook, and how they might influence the markets.

• Volume Anomalies: Identify stocks witnessing unusual trading volumes, pointing to potential opportunities or risks.

• Top Pre-Market Movers: Identify early winners poised for a strong market opening.

• Market Indices & Sector Overview: Get a snapshot of key market indices and sector performances to gauge the day's potential trends.

• FDA Approvals & Upcoming Decisions: Keep an eye on the latest FDA approvals and crucial upcoming decisions affecting biotech and pharmaceutical stocks.

Now, let's dive into today's edition for a closer look at the insights and analysis that will shape your trading decisions.

Happening Today

✓ 08:30 AM ET – Initial Jobless Claims

✓ 08:30 AM ET – Continuing Jobless Claims

✓ 08:30 AM ET – Philadelphia Fed Manufacturing Index (Apr)

✓ 09:15 AM ET – FOMC Member Bowman Speaks

✓ 10:00 AM ET – Existing Home Sales (Mar)

PREMARKET SNAPSHOT 📈

Stock Futures dip, with the NASDAQ 100 leading the way down 1.24%.

SECTOR SNAPSHOT ✨

Most sectors closed down with Information Technology leading the decline at -1.71%, while Utilities bucked the trend with a gain of 2.08%.

Unusual Volume

📈 SINTX Technologies Inc (SINT) jumped 62.88% to $0.04 on a whopping 472.84 million shares traded after it announced pricing of $1.5 million public offering of common stock.

📈 Investors went wild, sending INVO Bioscience Inc (INVO) stock soaring 139.47% to $1.82 on a massive volume of 225.96 million shares after reporting fourth quarter and full year 2023 financial results.

📈 Abnormal activity shook WiSA Technologies Inc (WISA), pushing it up 51.64% to $9.25 on a whopping 67.46 million shares traded. The company’s subsidiary WiSA Association announced that it has executed its fourth 5-year WiSA E licensing agreement with a fourth major HDTV/PTV (Projection TV) brand.

📈 United Airlines Holdings Inc (UAL) stock recently closed 17.45% upper at $48.74 on substantial volume of 67.15 million shares. This unusual activity came after the company declared first-quarter 2024 financial results and exceeded revenue and EPS expectations.

📈 Spectaire Holdings Inc (SPEC) decrease by -2.48% in a single trading session, with abnormally high trading volume of 54.03 million shares. The company announced strategic distribution partnership with a Fortune 1000 Energy Company.

Premarket Movers

Tian Ruixiang Holdings Ltd (TIRX) experiences a substantial 215.63% surge in pre-market trading following the filing of 6-K form with the SEC.

TH International Limited (THCH) sees a significant 13.46% increase, reaching a pre-market price of $1.18 after announcing fourth quarter and full year 2023 financial results.

Benitec Biopharma Inc. (BNTC) demonstrates a noteworthy 19.88% surge, with a pre-market price of $5.97. The company reported positive interim clinical trial data for first OPMD subject treated with BB-301 in phase 1b/2a study.

Important FDA 

Recently Announced

Johnson & Johnson (JNJ) received FDA approval on April 5, 2024, for Carvykti's expanded use in treating adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy.

AbbVie (ABBV) achieved a pivotal moment on April 5, 2024, as ELAHERE received full FDA approval for certain ovarian cancer patients, transitioning from its initial accelerated approval.

Bristol-Myers Squibb Co. (BMY) celebrated a significant milestone on April 5, 2024, with the FDA's approval of Opdivo, in combination with cisplatin-based chemotherapy, as a frontline option for adult patients with unresectable or metastatic urothelial carcinoma.

Upcoming Announcements

ImmunityBio, Inc. (IBRX) eagerly awaits the FDA's decision on April 23, 2024, regarding N-803 plus BCG in high-risk non-muscle-invasive bladder cancer. This resubmitted BLA holds the potential to offer a significant therapeutic advancement in the treatment landscape for this challenging condition, with hopes high for a positive outcome.

Aquestive Therapeutics Inc. (AQST) anticipates the FDA's decision on April 28, 2024, regarding Libervant for the treatment of seizure clusters in patients between two and five years of age. This NDA submission represents a critical step forward in addressing an unmet medical need in pediatric epilepsy, and the company eagerly awaits the regulatory verdict.

PharmaTher Holdings Ltd. (PHRRF.OB) awaits the FDA's decision on April 29, 2024, regarding KETARX as a potential treatment for anesthesia, sedation, pain, mental health, and neurological indications. The outcome of this ANDA submission could potentially open new avenues in various therapeutic areas, and the company looks forward to the regulatory determination.

🎁 Looking for More? Check out these complementary newsletters for diverse perspectives:

Happy investing,

Maeve Grace
Editor In Chief
Premium Trade Alerts

Important: This newsletter does not provide investment advice. The stocks mentioned should not be taken as recommendations. Your investments are solely your decisions.

Disclosure: I hold no positions in any companies mentioned, either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article.